DICE Therapeutics, Inc.
News
What 9 Analyst Ratings Have To Say About DICE Therapeutics
Benzinga Analysts have provided the following ratings for DICE Therapeutics DICE within the last quarter: These 9 analysts have an average price target of $50.78 versus the current price of DICE Therapeutics at $47.55, implying upside. Below is a summary of how these 9 analysts rated DICE Therapeutics over the past 3 months.\n more…
Lilly Completes Acquisition of DICE Therapeutics
PR Newswire Lilly Completes Acquisition of DICE Therapeutics Lilly Completes Acquisition of DICE Therapeutics PR Newswire INDIANAPOLIS, Aug. 9, 2023 INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of DICE Therapeutics...\n more…
Brokerages Set DICE Therapeutics, Inc. (NASDAQ:DICE) PT at $63.60
Zolmax Shares of DICE Therapeutics, Inc. (NASDAQ:DICE Get Free Report) have earned a consensus recommendation of Hold from the thirteen analysts that are presently covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a hold recommendation and six have assigned ...\n more…
Brokerages Set DICE Therapeutics, Inc. (NASDAQ:DICE) PT at $63.60
Ticker Report DICE Therapeutics, Inc. (NASDAQ:DICE Get Free Report) has been assigned a consensus recommendation of Hold from the thirteen ratings firms that are covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation and six ...\n more…
Lilly Announces Extension of Tender Offer to Acquire DICE
PR Newswire Lilly Announces Extension of Tender Offer to Acquire DICE Lilly Announces Extension of Tender Offer to Acquire DICE PR Newswire INDIANAPOLIS, July 25, 2023 INDIANAPOLIS, July 25, 2023 /PRNewswire...\n more…
7,770 Shares in DICE Therapeutics, Inc. (NASDAQ:DICE) Acquired by CM Wealth Advisors LLC
Zolmax CM Wealth Advisors LLC bought a new position in DICE Therapeutics, Inc. (NASDAQ:DICE Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 7,770 shares of the companys stock, valued at approximately $255,000. Several other hedge...\n more…